Today: 10 November 2025
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Lockheed Martin Stock Soars on Earnings Beat – “We’re an arm of the U.S. government,” analyst quips

Lockheed Martin Stock Soars on Earnings Beat – “We’re an arm of the U.S. government,” analyst quips

Robust Q3 Results and Increased Guidance Lockheed Martin’s (NYSE:LMT) Oct. 21 earnings release blew past forecasts, reflecting surging military demand. Revenue rose 8.8% year-over-year to $18.61 billion and net income was $6.95/share seattlepi.com. That beat Wall Street’s $6.33/share estimate and matched analyst forecasts of about $18.56 billion. CEO Jim Taiclet highlighted the “unprecedented demand” for Lockheed products, noting a record $179 billion backlog – over 2½ years of sales news.lockheedmartin.com. In light of the strong quarter, Lockheed raised 2025 guidance. It now expects $22.15–$22.35 EPS (vs prior $21.70–$22.00) and about $74.25–$74.75 billion in revenue reuters.com. Jim Taiclet emphasized the scale of current demand: “Based
21 October 2025
 ·  ·  ·  ·  · 
Coca-Cola Crushes Q3 Forecasts as Soda Sales Stay Hot – Stock Jumps

Coca-Cola Crushes Q3 Forecasts as Soda Sales Stay Hot – Stock Jumps

Strong Q3 Performance Beats Estimates Coca-Cola’s (NYSE: KO) Q3 2025 report blew past Wall Street’s forecasts. The beverage giant logged $12.5 billion in revenue, up 5% from last year (organic sales +6%) stocktitan.net. This exceeded the ~$12.39 billion consensus reuters.com. Volume was flat to slightly positive (+1%), but robust price/mix (+6%) drove growth. As a result, EPS of $0.86 surged 30% year-over-year stocktitan.net, topping the $0.78 street estimate reuters.com by 4 cents. Even excluding special items, Coke’s adjusted EPS of $0.82 comfortably beat forecasts. Notably, operating profit jumped 59% (29% currency-neutral) with an operating margin of 32.0% (vs 21.2% a year ago)
21 October 2025
 ·  ·  ·  ·  · 
Kraken Lists ASTER: Is This New DeFi Token the Next Big Thing?

Kraken Lists ASTER: Is This New DeFi Token the Next Big Thing?

A deeper look shows Kraken’s move brings a sophisticated DeFi token to its exchange. According to Kraken, ASTER is “a next-gen decentralized exchange offering spot and perpetual trading” across multiple chains blog.kraken.com. Its technology includes MEV-free execution and on-chain perpetuals (even a 1,001x leverage mode) with innovative collateral features blog.kraken.com binance.com. In practice, Aster lets traders earn yield on collateral like liquid-staked BNB (asBNB) and use a native stablecoin (USDF) to improve capital efficiency blog.kraken.com. (Binance Academy explains Aster uses advanced zero-knowledge proofs to protect trades from front-running and allow assets to earn yield as collateral binance.com.) In early October
21 October 2025
 ·  ·  ·  · 
Lynas Rare Earths (LYSCF) Stock Soars on $8.5B U.S.–Australia Rare-Earth Pact

Lynas Rare Earths (LYSCF) Stock Soars on $8.5B U.S.–Australia Rare-Earth Pact

Full Story: Below we examine Lynas Rare Earths’ recent news flow, stock trends, growth plans, and expert analysis in detail. Stock Performance & Recent Trend Lynas shares have been on a tear. By mid-October 2025, the stock (ASX: LYC) had nearly tripled in a year (from ≈A$6 in late 2024 to ~$19) investing.com ts2.tech. In early October it spiked to A$21.96 (its highest since 2011) investing.com on the magnet-chain MoU, then eased back to ~$18–19 as traders locked in profits ts2.tech. In late Oct 20–21 trading it jumped again (+15% on Oct 20) stockanalysis.com. By Oct 21 LYC was ~A$19 (US$14) investing.com
21 October 2025
 ·  ·  ·  · 
Alcoa (AA) Stock Poised for Breakout? Gallium Project, Tariff Relief & $40 Target Stun Investors

Alcoa (AA) Stock Poised for Breakout? Gallium Project, Tariff Relief & $40 Target Stun Investors

Alcoa’s stock story is a mix of bullish projects and market risks. The recent government-backed gallium plant (critical mineral for tech and defense) is a major positive, potentially diversifying Alcoa’s business beyond aluminium. Yet the industry is grappling with high US tariffs and costs. Below we break down these developments and what analysts are saying. Government support and the new Gallium project On Oct. 20, Alcoa announced that US and Australian agencies will provide funding for a joint venture to build a gallium plant at Alcoa’s Wagerup alumina refinery in Western Australia news.alcoa.com. In August Alcoa and a Japanese-US-Australian venture
21 October 2025
 ·  ·  ·  ·  · 
Stratasys (SSYS) Stock Surges 14%: Why 3D Printing Shares Are Heating Up

Stratasys (SSYS) Stock Surges 14%: Why 3D Printing Shares Are Heating Up

In summary, Stratasys’s stock has surged to multi-month highs on a combination of company-specific catalysts and broader market tailwinds. Recent acquisitions (Forward AM, Nexa3D), strategic partnerships (e.g. Toyota), and solid quarterly results have helped offset lingering macro uncertainty. Analysts remain cautious (average price targets near $13), but insiders emphasize that the core additive-manufacturing trend remains intact 3dprint.com investors.stratasys.com. With the U.S. manufacturing cycle poised for recovery and Fed policy possibly loosening, many experts see potential upside for SSYS in late 2025 and beyond – though they warn that customer spending could stay restrained until the economy stabilizes finviz.com investors.stratasys.com. Sources:
21 October 2025
 ·  ·  ·  ·  · 
HeartCore (HTCR) Stock Soars on Dividend Surprise – Analysts Weigh In

HeartCore (HTCR) Stock Soars on Dividend Surprise – Analysts Weigh In

Stock Performance & Dividend Announcement HTCR’s stock surged on Oct. 20, 2025, when the company revealed the $0.13/share dividend globenewswire.com. In after-hours trading, the share price jumped roughly 40% investing.com. (According to Investing.com, HeartCore stock “surged 40% in after-hours trading on Monday” after the dividend news investing.com.) By Oct. 21, HTCR traded around $0.71 reuters.com. The stock’s 52-week range is $0.39–$3.38 stockanalysis.com, reflecting swings earlier this year (it spiked above $3 in early 2025 before retreating). The dividend announcement itself was a headline event. In a GlobeNewswire release on Oct. 20, HeartCore said the one-time $0.13 payment represents ~17.8% of
21 October 2025
 ·  ·  ·  ·  · 
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside. Beam’s stock jumped sharply after the FDA awarded priority designations to its gene-editing therapies. On Oct 20,
21 October 2025
 ·  ·  ·  ·  · 
DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

Stock Surges on SteadyMD Acquisition DocGo’s shares jumped more than 34% in after-hours trading on Oct. 20, 2025, after the company announced it would acquire SteadyMD, a virtual care platform. According to an Investing.com report, DocGo stock “surged 34.6% in after-hours trading Monday following the company’s announcement that it has acquired virtual care platform SteadyMD” m.uk.investing.com. The acquisition was disclosed on Monday, Oct. 20, and a conference call to discuss it was scheduled for Oct. 21. SteadyMD brings a nationwide telehealth network (600+ clinicians serving ~3 million patients in 2025) to DocGo’s existing mobile health and ambulance services citybiz.co m.uk.investing.com.
21 October 2025
 ·  ·  ·  ·  · 
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) stockanalysis.com. Trading volume is light (hundreds of thousands of shares), and the stock’s beta (~1.46) indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average (~$2.03) and 200-day average (~$1.83) (see data marketbeat.com) suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average. Recent Developments gsk.com gsk.com At IDWeek
21 October 2025
 ·  ·  ·  ·  ·  · 
Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Stock Performance and Recent Rally Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that day marketbeat.com. (On Oct 21, REPL was trading around $8.95 reuters.com.) This reversed a mid-year collapse – in July 2025 a disappointing FDA Complete Response Letter caused the stock to collapse ~73% in one day globenewswire.com. Over the past year the 52-week trading range is roughly $2.68 (low) to $17.00 (high) marketbeat.com, reflecting that roller-coaster. Institutional interest remains high: recently hedge funds like TD Asset Management increased their
21 October 2025
 ·  ·  ·  ·  · 
1 … 53 54 55 56 57 … 171
Go toTop